Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
14
05
2020
accepted:
08
10
2020
revised:
24
09
2020
pubmed:
23
10
2020
medline:
9
7
2021
entrez:
22
10
2020
Statut:
ppublish
Résumé
Vitamin D (Vit-D), an essential nutrient, interacts with different drugs including chemotherapeutic agents like busulphan, an alkylating agent used for conditioning prior to stem cell transplantation. The correlation between Vit-D plasma levels and busulphan clearance was investigated in an uncontrolled prospective study in patients and mice. Plasma 25(OH)D levels were measured and busulphan pharmacokinetics calculated in 81 patients. Adults received oral busulphan (n = 34) while children received busulphan orally (n = 19) or intravenously (n = 28). Patients received no Vit-D supplementation. To confirm our findings, pharmacokinetics after a single dose of busulphan (oral or intravenous) were evaluated in two groups of mice (n = 60) receiving high or standard-level Vit-D supplementation. Both busulphan clearance (P < 0.0001) and 25(OH)D levels (P = 0.0004) were significantly higher in adults compared to children. A significant negative correlation (P = 0.041) was found between busulphan clearance and 25(OH)D levels in children treated orally. No such correlation was observed in adults or in children receiving intravenous busulphan. In addition, no significant effect of Vit-D levels on busulphan pharmacokinetics in mice regardless of the administration route. In conclusion, 25(OH)D can affect oral busulphan pharmacokinetics in children and its level should be considered when personalizing oral busulphan treatment. Further studies are warranted to confirm the underlying mechanisms.
Identifiants
pubmed: 33087877
doi: 10.1038/s41409-020-01091-y
pii: 10.1038/s41409-020-01091-y
doi:
Substances chimiques
Vitamin D
1406-16-2
Busulfan
G1LN9045DK
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
807-817Références
Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18–25. quiz 26.
pubmed: 8342071
Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma. 1996;22:395-&.
doi: 10.3109/10428199609054777
Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transpl. 2008;14:220–8.
doi: 10.1016/j.bbmt.2007.10.028
Andersson BS, Thall PF, Madden T, Couriel D, Wang XM, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477–85.
pubmed: 12374452
doi: 10.1053/bbmt.2002.v8.pm12374452
Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20:543–9.
pubmed: 9780133
doi: 10.1097/00007691-199810000-00017
Hassan M, El-Serafi I. Personalized treatment: the future of medicine. A perspective on the preconditioning for stem cell transplantation. MOJ Cell Sci Rep. 2015;2:81–3.
doi: 10.15406/mojcsr.2015.02.00032
Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, et al. Personalizing Busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22:1915–25. https://doi.org/10.1016/j.bbmt.2016.07.013 .
pubmed: 27481448
doi: 10.1016/j.bbmt.2016.07.013
Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, et al. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014;74:927–38.
pubmed: 25163570
pmcid: 4210372
doi: 10.1007/s00280-014-2571-0
Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, et al. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2013;19:1608–14.
doi: 10.1016/j.bbmt.2013.08.014
ten Brink MH, van Bavel T, Swen JJ, van der Straaten T, Bredius RGM, Lankester AC, et al. Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics. 2013;14:1683–90.
pubmed: 24192117
doi: 10.2217/pgs.13.159
Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res. 1996;16:2083–8.
pubmed: 8712747
El-Serafi I, Terelius Y, Abedi-Valugerdi M, Naughton S, Saghafian M, Moshfegh A, et al. Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. PLoS One. 2017;12:e0187294.
pubmed: 29121650
pmcid: 5679629
doi: 10.1371/journal.pone.0187294
Hassan M, Svensson JO, Nilsson C, Hentschke P, Al-Shurbaji A, Aschan J, et al. Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy. Ther Drug Monit. 2000;22:383–5.
pubmed: 10942175
doi: 10.1097/00007691-200008000-00003
Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transpl. 2003;31:429–35.
doi: 10.1038/sj.bmt.1703896
Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21:319–29.
pubmed: 24529992
pmcid: 3968073
doi: 10.1016/j.chembiol.2013.12.016
Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.
pubmed: 21118827
doi: 10.1210/jc.2010-2704
Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human Skin. J Clin Endocrinol Metab. 1988;67:373–8.
pubmed: 2839537
doi: 10.1210/jcem-67-2-373
Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA. 2004;101:7711–5.
pubmed: 15128933
doi: 10.1073/pnas.0402490101
pmcid: 419671
Holick MF. Vitamin D deficiency. N. Engl J Med. 2007;357:266–81.
pubmed: 17634462
doi: 10.1056/NEJMra070553
Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer. 2006;119:1819–28.
pubmed: 16708384
doi: 10.1002/ijc.22058
Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90:3215–24.
pubmed: 15797954
doi: 10.1210/jc.2004-2364
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.
pubmed: 21646368
doi: 10.1210/jc.2011-0385
Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Alter Med Rev. 2008;13:6–20.
Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50:20.
pmcid: 5938036
Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, et al. Effect of high-dose vs standard-dose vitamin D3 supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: the SUNSHINE randomized clinical trial. JAMA. 2019;321:1370–9.
pubmed: 30964527
pmcid: 6459117
doi: 10.1001/jama.2019.2402
Chae YJ, Cho KH, Yoon IS, Noh CK, Lee HJ, Park Y, et al. Vitamin D receptor-mediated upregulation of CYP3A4 and MDR1 by quercetin in Caco-2 cells. Planta Med. 2016;82:121–30.
pubmed: 26366751
Wang ZC, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013;136:54–8.
pubmed: 22985909
doi: 10.1016/j.jsbmb.2012.09.012
Wigington DP, Urben CM, Strugnell SA, Knutson JC. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res. 2004;24:2905–12.
pubmed: 15517895
Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Sura T, Ungkanont A, et al. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am J Hematol. 2007;82:1095–8.
pubmed: 17674372
doi: 10.1002/ajh.21002
Leblanc AF, Huang KM, Uddin ME, Anderson JT, Chen M, Hu S. Murine pharmacokinetic studies. Bio Protoc. 2018;8:e3056.
pubmed: 31106235
pmcid: 6521687
doi: 10.21769/BioProtoc.3056
Lang E, Jilani K, Bissinger R, Rexhepaj R, Zelenak C, Lupescu A, et al. Vitamin D-rich diet in mice modulates erythrocyte survival. Kidney Blood Press Res. 2015;40:403–12.
pubmed: 26227001
doi: 10.1159/000368517
Lewis CA, Manning J, Barr C, Peake K, Humphries RK, Rossi F, et al. Myelosuppressive conditioning using busulfan enables bone marrow cell accumulation in the spinal cord of a mouse model of amyotrophic lateral sclerosis. PLoS ONE. 2013;8:e60661.
pubmed: 23593276
pmcid: 3620474
doi: 10.1371/journal.pone.0060661
Peake K, Manning J, Lewis CA, Barr C, Rossi F, Krieger C. Busulfan as a myelosuppressive agent for generating stable high-level bone marrow chimerism in mice. J Vis Exp. 2015;e52553. https://doi.org/10.3791/52553 .
Sjoo F, El-Serafi I, Enestig J, Mattsson J, Liwing J, Hassan M. Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate. Clin Drug Investig. 2013. https://doi.org/10.1007/s40261-013-0148-z .
Riley RS, Idowu M, Chesney A, Zhao S, McCarty J, Lamb LS, et al. Hematologic aspects of myeloablative therapy and bone marrow transplantation. J Clin Lab Anal. 2005;19:47–79.
pubmed: 15756708
pmcid: 6807857
doi: 10.1002/jcla.20055
Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. 2008;299:925–36. e-pub ahead of print 2008/03/04[pii]. https://doi.org/10.1001/jama.299.8.925 .
pubmed: 18314435
doi: 10.1001/jama.299.8.925
Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569–74.
pubmed: 11739158
doi: 10.1182/blood.V98.13.3569
McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39:155–65.
pubmed: 10976660
doi: 10.2165/00003088-200039020-00005
Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Eff Outcomes Clin Pharmacokinet. 1997;32:324–43.
doi: 10.2165/00003088-199732040-00005
Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et al. Busulfan bioavailability. Blood. 1994;84:2144–50.
pubmed: 7919328
doi: 10.1182/blood.V84.7.2144.2144
Andersson BS, Bhagwatwar HP, Chow DS. Parenteral busulfan for treatment of malignant disease. Google Patents; 1995.
Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. IV busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33:979.
pubmed: 15064687
doi: 10.1038/sj.bmt.1704446
Malar R, Sjoo F, Rentsch K, Hassan M, Gungor T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transpl. 2011;15:580–8.
Wallace G, Jodele S, Howell J, Myers KC, Teusink A, Zhao X, et al. Vitamin D deficiency and survival in children after hematopoietic stem cell transplant. Biol Blood Marrow Transpl. 2015;21:1627–31.
doi: 10.1016/j.bbmt.2015.06.009
Peng J, Liu Y, Xie J, Yang G, Huang Z. Effects of vitamin D on drugs: response and disposal. Nutrition. 2020;74:110734. e-pub ahead of print 2020/03/18.
pubmed: 32179384
doi: 10.1016/j.nut.2020.110734
Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharm Ther. 2009;85:198–203. e-pub ahead of print 2008/08/30.
doi: 10.1038/clpt.2008.165
Hansson ME, Norlin AC, Omazic B, Wikstrom AC, Bergman P, Winiarski J, et al. Vitamin d levels affect outcome in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2014;20:1537–43.
doi: 10.1016/j.bbmt.2014.05.030
Liu C, Weng H, Chen L, Yang S, Wang H, Debnath G, et al. Impaired intestinal calcium absorption in protein 4.1R-deficient mice due to altered expression of plasma membrane calcium ATPase 1b (PMCA1b). J Biol Chem. 2013;288:11407–15. e-pub ahead of print 2013/03/06.
pubmed: 23460639
pmcid: 3630858
doi: 10.1074/jbc.M112.436659
Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood. 1990;75:1723–7. e-pub ahead of print 1990/04/15.
pubmed: 2328321
doi: 10.1182/blood.V75.8.1723.1723
Wong GK, Shulman RJ, Chumpitazi BP. Gastric emptying scintigraphy results in children are affected by age, anthropometric factors, and study duration. Neurogastroenterol Motil. 2015;27:356–62. e-pub ahead of print 2015/01/06.
pubmed: 25557417
pmcid: 4339628
doi: 10.1111/nmo.12499
Giraldi G, Fioravanti A, De Luca d’Alessandro E, Palmery M, Martinoli L. Investigation of the effects of vitamin D and calcium on intestinal motility: in vitro tests and implications for clinical treatment. Acta Pharm. 2015;65:343–9. e-pub ahead of print 2015/10/03.
pubmed: 26431111
doi: 10.1515/acph-2015-0023
Kedar A, Nikitina Y, Henry OR, Abell KB, Vedanarayanan V, Griswold ME, et al. Gastric dysmotility and low serum vitamin D levels in patients with gastroparesis. Horm Metab Res. 2013;45:47–53. e-pub ahead of print 2012/09/08.
pubmed: 22956309
Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma. 1996;22:395–407.
pubmed: 8882952
doi: 10.3109/10428199609054777
Assa A, Vong L, Pinnell LJ, Avitzur N, Johnson-Henry KC, Sherman PM. Vitamin D deficiency promotes epithelial barrier dysfunction and intestinal inflammation. J Infect Dis. 2014;210:1296–305. e-pub ahead of print 2014/04/24.
pubmed: 24755435
doi: 10.1093/infdis/jiu235
Pielichowski W, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, Rzepecki P. Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J BUON. 2011;16:541–6.
pubmed: 22006763
Hassan M, Ehrsson H. Metabolism of 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet. 1987;12:71–6. e-pub ahead of print 1987/01/01.
pubmed: 3609074
doi: 10.1007/BF03189864
Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat. Drug Metab Dispos. 1987;15:399–402. e-pub ahead of print 1987/05/01.
pubmed: 2886318
Hassan M, Ehrsson H, Wallin I, Eksborg S. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. Eur J Drug Metab Pharmacokinet. 1988;13:301–5. e-pub ahead of print 1988/10/01.
pubmed: 3243326
doi: 10.1007/BF03190094
Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharm. 1989;36:525–30. e-pub ahead of print 1989/01/01.
doi: 10.1007/BF00558081
McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014;20:754–63.
doi: 10.1158/1078-0432.CCR-13-1960
pubmed: 24218510
Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996;24:1015–9.
pubmed: 8886613
Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996;56:3678–81.
pubmed: 8706007
Gibbs JP, Yang JS, Slattery JT. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Drug Metab Dispos. 1998;26:52–5.
pubmed: 9443852
Herman TF, Santos C. First Pass Effect. In: StatPearls: Treasure Island (FL); 2020.
Uppugunduri CR, Rezgui MA, Diaz PH, Tyagi AK, Rousseau J, Daali Y, et al. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J. 2014;14:263–71.
pubmed: 24165757
doi: 10.1038/tpj.2013.38
Qin X, Wang X. Role of vitamin D receptor in the regulation of CYP3A gene expression. Acta Pharm Sin B. 2019;9:1087–98.
pubmed: 31867158
pmcid: 6900549
doi: 10.1016/j.apsb.2019.03.005
Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277:25125–32.
pubmed: 11991950
doi: 10.1074/jbc.M201323200
Tateishi T, Nakura H, Asoh M, Watanabe M, Tanaka M, Kumai T, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci. 1997;61:2567–74.
pubmed: 9416779
doi: 10.1016/S0024-3205(97)01011-4
Beath SV. Hepatic function and physiology in the newborn. Semin Neonatol. 2003;8:337–46.
pubmed: 15001122
doi: 10.1016/S1084-2756(03)00066-6
Ginty F, Cavadini C, Michaud PA, Burckhardt P, Baumgartner M, Mishra GD, et al. Effects of usual nutrient intake and vitamin D status on markers of bone turnover in Swiss adolescents. Eur J Clin Nutr. 2004;58:1257–65.
pubmed: 15054442
doi: 10.1038/sj.ejcn.1601959
Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004;158:531–7.
pubmed: 15184215
doi: 10.1001/archpedi.158.6.531
Balasubramanian S, Ganesh R. Vitamin D deficiency in exclusively breast-fed infants. Indian J Med Res. 2008;127:250–5.
pubmed: 18497439